File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitleSerum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
 
AuthorsHui, CK1
Zhang, HY1
Lee, NP1
Chan, W1
Yueng, YH1
Leung, KW1
Lu, L1
Leung, N2
Lo, CM1
Fan, ST1
Luk, JM1
Xu, A1
Lam, KS1
Kwong, YL1
Lau, GKK1
 
KeywordsAdiponectin
Adiponectin oligomeric form
Chronic hepatitis B
Lamivudine
Liver cirrhosis
Pegylated interferon alfa-2a
Sustained virological response
 
Issue Date2007
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationJournal Of Hepatology, 2007, v. 47 n. 2, p. 191-202 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2007.02.023
 
AbstractBackground/Aims: Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts. Methods: Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n = 15), pegylated interferon alfa-2a (n = 15) or pegylated interferon alfa-2a plus lamivudine (n = 8) therapy for 48 weeks were assessed. Results: Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r = 0.45, p < 0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean ± SEM 51.2 ± 2.1% vs. 40.9 ± 1.7%, respectively, p = 0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean ± SEM 43.5 ± 1.2% vs. 37.0 ± 3.0%, respectively, p = 0.04]. Conclusions: Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction. © 2007 European Association for the Study of the Liver.
 
ISSN0168-8278
2013 Impact Factor: 10.401
 
DOIhttp://dx.doi.org/10.1016/j.jhep.2007.02.023
 
ISI Accession Number IDWOS:000248642400006
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHui, CK
 
dc.contributor.authorZhang, HY
 
dc.contributor.authorLee, NP
 
dc.contributor.authorChan, W
 
dc.contributor.authorYueng, YH
 
dc.contributor.authorLeung, KW
 
dc.contributor.authorLu, L
 
dc.contributor.authorLeung, N
 
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.contributor.authorLuk, JM
 
dc.contributor.authorXu, A
 
dc.contributor.authorLam, KS
 
dc.contributor.authorKwong, YL
 
dc.contributor.authorLau, GKK
 
dc.date.accessioned2010-09-06T07:34:30Z
 
dc.date.available2010-09-06T07:34:30Z
 
dc.date.issued2007
 
dc.description.abstractBackground/Aims: Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts. Methods: Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n = 15), pegylated interferon alfa-2a (n = 15) or pegylated interferon alfa-2a plus lamivudine (n = 8) therapy for 48 weeks were assessed. Results: Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r = 0.45, p < 0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean ± SEM 51.2 ± 2.1% vs. 40.9 ± 1.7%, respectively, p = 0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean ± SEM 43.5 ± 1.2% vs. 37.0 ± 3.0%, respectively, p = 0.04]. Conclusions: Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction. © 2007 European Association for the Study of the Liver.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Hepatology, 2007, v. 47 n. 2, p. 191-202 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2007.02.023
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2007.02.023
 
dc.identifier.epage202
 
dc.identifier.hkuros133098
 
dc.identifier.isiWOS:000248642400006
 
dc.identifier.issn0168-8278
2013 Impact Factor: 10.401
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmid17462782
 
dc.identifier.scopuseid_2-s2.0-34347389866
 
dc.identifier.spage191
 
dc.identifier.urihttp://hdl.handle.net/10722/77676
 
dc.identifier.volume47
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.
 
dc.subject.meshAdiponectin - blood - chemistry - genetics
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 and over
 
dc.subject.meshAntiviral Agents - therapeutic use
 
dc.subject.meshCohort Studies
 
dc.subject.meshDisease Progression
 
dc.subject.meshEnzyme-Linked Immunosorbent Assay
 
dc.subject.meshFemale
 
dc.subject.meshHepatitis B, Chronic - complications - drug therapy - pathology
 
dc.subject.meshHumans
 
dc.subject.meshImmunohistochemistry
 
dc.subject.meshLiver - metabolism
 
dc.subject.meshLiver Cirrhosis - blood - metabolism - pathology - virology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshMolecular Weight
 
dc.subject.meshRNA, Messenger - metabolism
 
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
 
dc.subject.meshSeverity of Illness Index
 
dc.subjectAdiponectin
 
dc.subjectAdiponectin oligomeric form
 
dc.subjectChronic hepatitis B
 
dc.subjectLamivudine
 
dc.subjectLiver cirrhosis
 
dc.subjectPegylated interferon alfa-2a
 
dc.subjectSustained virological response
 
dc.titleSerum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Hui, CK</contributor.author>
<contributor.author>Zhang, HY</contributor.author>
<contributor.author>Lee, NP</contributor.author>
<contributor.author>Chan, W</contributor.author>
<contributor.author>Yueng, YH</contributor.author>
<contributor.author>Leung, KW</contributor.author>
<contributor.author>Lu, L</contributor.author>
<contributor.author>Leung, N</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<contributor.author>Luk, JM</contributor.author>
<contributor.author>Xu, A</contributor.author>
<contributor.author>Lam, KS</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<contributor.author>Lau, GKK</contributor.author>
<date.accessioned>2010-09-06T07:34:30Z</date.accessioned>
<date.available>2010-09-06T07:34:30Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Journal Of Hepatology, 2007, v. 47 n. 2, p. 191-202</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77676</identifier.uri>
<description.abstract>Background/Aims: Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts. Methods: Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n = 15), pegylated interferon alfa-2a (n = 15) or pegylated interferon alfa-2a plus lamivudine (n = 8) therapy for 48 weeks were assessed. Results: Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r = 0.45, p &lt; 0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean &#177; SEM 51.2 &#177; 2.1% vs. 40.9 &#177; 1.7%, respectively, p = 0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean &#177; SEM 43.5 &#177; 1.2% vs. 37.0 &#177; 3.0%, respectively, p = 0.04]. Conclusions: Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction. &#169; 2007 European Association for the Study of the Liver.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<rights>Journal of Hepatology. Copyright &#169; Elsevier BV.</rights>
<subject>Adiponectin</subject>
<subject>Adiponectin oligomeric form</subject>
<subject>Chronic hepatitis B</subject>
<subject>Lamivudine</subject>
<subject>Liver cirrhosis</subject>
<subject>Pegylated interferon alfa-2a</subject>
<subject>Sustained virological response</subject>
<subject.mesh>Adiponectin - blood - chemistry - genetics</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 and over</subject.mesh>
<subject.mesh>Antiviral Agents - therapeutic use</subject.mesh>
<subject.mesh>Cohort Studies</subject.mesh>
<subject.mesh>Disease Progression</subject.mesh>
<subject.mesh>Enzyme-Linked Immunosorbent Assay</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - complications - drug therapy - pathology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunohistochemistry</subject.mesh>
<subject.mesh>Liver - metabolism</subject.mesh>
<subject.mesh>Liver Cirrhosis - blood - metabolism - pathology - virology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Molecular Weight</subject.mesh>
<subject.mesh>RNA, Messenger - metabolism</subject.mesh>
<subject.mesh>Reverse Transcriptase Polymerase Chain Reaction</subject.mesh>
<subject.mesh>Severity of Illness Index</subject.mesh>
<title>Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0168-8278&amp;volume=47&amp;issue=2&amp;spage=191&amp;epage=202&amp;date=2007&amp;atitle=Serum+adiponectin+is+increased+in+advancing+liver+fibrosis+and+declines+with+reduction+in+fibrosis+in+chronic+hepatitis+B</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.jhep.2007.02.023</identifier.doi>
<identifier.pmid>17462782</identifier.pmid>
<identifier.scopus>eid_2-s2.0-34347389866</identifier.scopus>
<identifier.hkuros>133098</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-34347389866&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>47</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>191</identifier.spage>
<identifier.epage>202</identifier.epage>
<identifier.isi>WOS:000248642400006</identifier.isi>
<publisher.place>Netherlands</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Alice Ho Miu Ling Nethersole Hospital